PMID: 9450785Feb 5, 1998Paper

Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

British Journal of Haematology
E LengfelderR Hehlmann

Abstract

In order to evaluate the natural history of essential thrombocythaemia (ET), clinical data and prognostic factors of 143 patients with ET were retrospectively analysed (mean observation time 6.1 +/- 4.6 years). In 42 patients the early phase of the disease with initial platelet counts between 250 and 600 x 10(9)/l was assessed. In most early cases, ET was suggested by clinical symptoms (79%) and increased megakaryopoiesis (95%) with abnormal megakaryocytes in bone marrow histology (n = 34) and cytology (n = 5). Other myeloproliferative disorders and reactive thrombocytosis were excluded according to the diagnostic criteria of the Polycythemia Vera Study Group. During follow-up of the 38 early cases not treated cytoreductively at diagnosis, the platelet counts increased to >600 x 10(9)/l in 28 patients (74%) and remained between 450 and 600 x 10(9)/l in 10 patients (26%). In primarily asymptomatic patients (n = 46) with initial platelet counts above (n = 37) and below 600 x 10(9)/l (n = 9) the rates of increase of symptomatic patients were similar at about 7% per year. No influence of the initial platelet count on survival was seen in multivariate analysis of prognostic factors which included all 143 cases. Survival was mainly i...Continue Reading

References

Jan 1, 1978·Methods in Cell Biology·D E Comings
Feb 1, 1990·Pathology, Research and Practice·A GeorgiiM Werner
Jan 1, 1990·American Journal of Hematology·F E MillardG G Marino
May 1, 1990·Journal of Clinical Pathology·R BurkhardtG Helmer
Mar 1, 1988·Klinische Wochenschrift·B BaumannR Hehlmann
Jan 20, 1989·Klinische Wochenschrift·A HochhausM Meyer
Jun 1, 1986·Ultraschall in der Medizin : Organ der Deutschen Gesellschaft für Ultraschall in der Medizin, [der] Österreichischen Gesellschaft für Ultraschall in der Medizin, [der] Schweizerischen Gesellschaft für Ultraschall in Medizin und Biologie·K FrankH Wohlenberg
Nov 1, 1984·Pathology, Research and Practice·R BurkhardtM Sund
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
May 1, 1994·Progress in Cardiovascular Diseases·J S Alpert, J E Dalen

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Tiziano Barbui
Jan 1, 2009·Current Hematologic Malignancy Reports·Juergen Thiele, Hans Michael Kvasnicka
Oct 23, 2013·Current Hematologic Malignancy Reports·Hans Michael Kvasnicka
May 5, 1999·Critical Reviews in Oncology/hematology·T Barbui, G Finazzi
May 24, 2003·Best Practice & Research. Clinical Haematology·Michelle A Elliott, Ayalew Tefferi
Jun 13, 2002·British Journal of Haematology·Claire N Harrison
Apr 12, 2003·Seminars in Hematology·Tiziano Barbui
Apr 12, 2003·Seminars in Hematology·Harriet S Gilbert
Feb 4, 2006·Current Opinion in Hematology·Ayalew Tefferi
Jan 27, 2007·Current Opinion in Hematology·Ayalew Tefferi, James W Vardiman
Sep 13, 2000·Drugs & Aging·P J van Genderen, M M Troost
May 15, 2001·European Journal of Haematology·C A Wright, A Tefferi
Jan 7, 2006·Leukemia & Lymphoma·Juergen Thiele, Hans M Kvasnicka
Jan 26, 2005·British Journal of Haematology·M A Elliott, A Tefferi
Jul 21, 2005·British Journal of Haematology·Claire N Harrison
Aug 31, 2007·European Journal of Haematology. Supplementum·Martin Griesshammer
Nov 13, 2008·British Journal of Haematology·S K Austin, J R Lambert
Mar 25, 2010·British Journal of Haematology·Claire N HarrisonUNKNOWN British Committee for Standards in Haematology
Dec 25, 2008·Expert Review of Anticancer Therapy·Ashkan Emadi, Jerry L Spivak
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·J J Michiels
Oct 22, 2009·American Journal of Hematology·Hans Michael Kvasnicka, Juergen Thiele
May 27, 2009·Hematological Oncology·Martin Griesshammer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.